WallStreetZenWallStreetZen

NASDAQ: ALLO
Allogene Therapeutics Inc Stock Ownership - Who owns Allogene Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Allogene Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Benjamin Machinas BeneskiSVP Chief Technical Officer2026-03-164,835$2.47
$11.94kSell
David D. ChangPresident and CEO2026-03-1647,763$2.47
$117.97kSell
Benjamin Machinas BeneskiSVP Chief Technical Officer2026-03-027,132$2.60
$18.54kSell
Earl Martin DouglasSVP General Counsel2026-02-0222,900$1.76
$40.30kSell
Annie YoshiyamaSVP Finance2026-02-024,167$1.72
$7.17kSell
Zachary RobertsEVP of RD2026-02-0235,700$1.77
$63.19kSell
Geoffrey M. ParkerCHIEF FINANCIAL OFFICER2026-02-0224,001$1.76
$42.24kSell
Benjamin Machinas BeneskiSVP Chief Technical Officer2026-02-027,549$1.73
$13.06kSell
David D. ChangPresident and CEO2026-02-0295,269$1.80
$171.48kSell
Zachary RobertsEVP of RD2026-01-2126,269$1.56
$40.98kSell

1 of 2

ALLO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALLO insiders and whales buy or sell their stock.

ALLO Shareholders

What type of owners hold Allogene Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Pfizer Inc9.04%22,032,040$51.33MInsider
Pfizer Inc9.04%22,032,040$51.33MInstitution
Tpg GP A LLC7.68%18,716,306$43.61MInsider
Tpg GP A LLC7.68%18,716,306$43.61MInstitution
Tpg Group Holdings Sbs Advisors Inc7.68%18,716,306$43.61MInsider
Blackrock Inc7.25%17,676,029$41.19MInstitution
Citadel Advisors LLC4.97%12,111,420$28.22MInstitution
Vanguard Group Inc3.80%9,251,609$21.56MInstitution
Primecap Management Co3.34%8,139,840$18.97MInstitution
David D. Chang2.61%6,351,707$14.80MInsider

1 of 3

ALLO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALLO66.72%31.97%Net SellingNet Selling
MDXG46.84%53.16%Net BuyingNet Buying
IVA48.83%0.00%
TECX26.30%73.70%Net BuyingNet Selling
ZURA44.38%55.62%Net BuyingNet Buying
View Top Biotech Stocks

Allogene Therapeutics Stock Ownership FAQ

Who owns Allogene Therapeutics?

Allogene Therapeutics (NASDAQ: ALLO) is owned by 66.72% institutional shareholders, 31.97% Allogene Therapeutics insiders, and 1.32% retail investors. Pfizer Inc is the largest individual Allogene Therapeutics shareholder, owning 22.03M shares representing 9.04% of the company. Pfizer Inc's Allogene Therapeutics shares are currently valued at $53.10M.

If you're new to stock investing, here's how to buy Allogene Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.